JPH0952848A - Skin preparation for external use - Google Patents
Skin preparation for external useInfo
- Publication number
- JPH0952848A JPH0952848A JP22113795A JP22113795A JPH0952848A JP H0952848 A JPH0952848 A JP H0952848A JP 22113795 A JP22113795 A JP 22113795A JP 22113795 A JP22113795 A JP 22113795A JP H0952848 A JPH0952848 A JP H0952848A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- mpc
- sulfate
- polymer
- mucopolysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 14
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 11
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 claims description 6
- 239000006210 lotion Substances 0.000 abstract description 8
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 abstract description 6
- 229920001287 Chondroitin sulfate Polymers 0.000 abstract description 5
- 239000006071 cream Substances 0.000 abstract description 4
- 239000003505 polymerization initiator Substances 0.000 abstract description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 3
- 229920001499 Heparinoid Polymers 0.000 abstract description 3
- 229920000288 Keratan sulfate Polymers 0.000 abstract description 3
- 229920000669 heparin Polymers 0.000 abstract description 3
- 229960002897 heparin Drugs 0.000 abstract description 3
- 239000002554 heparinoid Substances 0.000 abstract description 3
- 229920002674 hyaluronan Polymers 0.000 abstract description 3
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 3
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract description 3
- 239000000843 powder Substances 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 229920000045 Dermatan sulfate Polymers 0.000 abstract description 2
- 229940094517 chondroitin 4-sulfate Drugs 0.000 abstract description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 abstract description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract description 2
- 229940051593 dermatan sulfate Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- RMVRNAXXHCXCLR-UHFFFAOYSA-N ethenyl 2-methylprop-2-enoate;2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical compound CC(=C)C(=O)OC=C.OCC[N+](C)(C)C#P=O RMVRNAXXHCXCLR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003906 humectant Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 10
- -1 organic acid salts Chemical class 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000010382 gamma-tocopherol Nutrition 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 239000002304 perfume Substances 0.000 description 5
- 239000002478 γ-tocopherol Substances 0.000 description 5
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940067596 butylparaben Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008309 hydrophilic cream Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- PJGSXAZUFMCQKA-UHFFFAOYSA-N 1-bromo-2-dichlorophosphorylethane Chemical compound ClP(Cl)(=O)CCBr PJGSXAZUFMCQKA-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VKCINEULROICJH-UHFFFAOYSA-N 2-dichlorophosphorylethanol Chemical compound OCCP(Cl)(Cl)=O VKCINEULROICJH-UHFFFAOYSA-N 0.000 description 1
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
- FQCSIUSICFAMDD-UHFFFAOYSA-N 2-oxopyrrolidine-1-carboxylic acid;sodium Chemical compound [Na].OC(=O)N1CCCC1=O FQCSIUSICFAMDD-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- ZDZANOOQZKTAFJ-UHFFFAOYSA-N C(CCC)OC(=O)C1=CC=C(O)C=C1.[O-2].[Zn+2] Chemical compound C(CCC)OC(=O)C1=CC=C(O)C=C1.[O-2].[Zn+2] ZDZANOOQZKTAFJ-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000020721 horse chestnut extract Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- DSGXMEGLIMXDNB-WGCWOXMQSA-M sodium;(e)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoate Chemical compound [Na+].COC1=CC=C(\C=C\C([O-])=O)C=C1O DSGXMEGLIMXDNB-WGCWOXMQSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は皮膚外用剤に関し、
詳しくは皮膚に対する保湿効果に優れ、且つ感触的にも
優れた皮膚外用剤を提供せんとするものである。TECHNICAL FIELD The present invention relates to an external preparation for skin,
More specifically, it is intended to provide a skin external preparation which is excellent in moisturizing effect on the skin and is also excellent in touch.
【0002】[0002]
【従来の技術】一般に皮膚の乾燥は、皮膚分泌物の量、
特に皮脂分泌量の減退により、角層のバリア機能が低下
し、経表皮性水分損失(以下、TEWLと略す)が大き
くなったときにおこる。従って冬季や、過剰な皮膚洗
浄、年齢、体質などによる皮膚分泌物の減少により皮膚
乾燥が増悪し、角層水分量が10%程度以下に低下した
状態を特にドライスキンと称している。このように皮膚
が乾燥状態になると皮膚のつやは低下し、小じわが目だ
つなどの弊害がでてくる。2. Description of the Related Art In general, drying of the skin depends on the amount of skin secretions,
Particularly, it occurs when the barrier function of the stratum corneum is lowered and transepidermal water loss (hereinafter abbreviated as TEWL) is increased due to the decrease in the amount of sebum secretion. Therefore, a condition in which dry skin is exacerbated in winter or due to excessive skin washing, age, constitution and the like, and skin dryness is exacerbated, and the water content of the stratum corneum is reduced to about 10% or less is particularly called dry skin. As described above, when the skin is in a dry state, the gloss of the skin decreases, and adverse effects such as fine wrinkles appear.
【0003】従来、これらの皮膚状態を改善するために
は、角層の水分含有量の低下を防止し、正常な機能を維
持することが必要であり、これまで各種の保湿剤と称す
るものが用いられてきた。すなわち、例えばソルビトー
ル、エチレングリコール、グリセリンなどの多価アルコ
ール類、ピロリドンカルボン酸ソーダ、乳酸ソーダなど
の有機酸塩類、コラーゲン、エラスチンなどのタン白質
類およびヒアルロン酸、コンドロイチン硫酸などのムコ
多糖類などである。Conventionally, in order to improve these skin conditions, it has been necessary to prevent a decrease in the water content of the stratum corneum and maintain a normal function. So far, various moisturizers have been known. Has been used. That is, for example, sorbitol, ethylene glycol, polyhydric alcohols such as glycerin, sodium pyrrolidone carboxylic acid, organic acid salts such as sodium lactate, collagen, proteins such as elastin and hyaluronic acid, mucopolysaccharides such as chondroitin sulfate. is there.
【0004】このような保湿剤の中にあっても、ムコ多
糖は皮膚中にも存在する生体成分であると同時に強力な
保湿作用を有するが故に、化粧料ばかりでなく医薬品分
野においても多用される重要な成分となっている。Among these moisturizers, mucopolysaccharide is a biological component that is also present in the skin and at the same time has a strong moisturizing action, and is therefore widely used not only in cosmetics but also in the pharmaceutical field. It is an important ingredient.
【0005】[0005]
【発明の解決しようとする課題】ところが、ムコ多糖は
強力な保湿作用を有する反面、べたつきの非常に強い使
用感触を有しており、皮膚外用剤特に化粧料に配合する
には難点となっていた。本発明は斯かる実情に鑑みてな
されたものであって、ムコ多糖の有する保湿作用を充分
に発揮しつつ、べたつきを抑えた皮膚外用剤を提供する
ことを課題とする。However, while mucopolysaccharide has a strong moisturizing effect, it has a very sticky feeling on use, which makes it difficult to mix it with external preparations for skin, especially cosmetics. It was The present invention has been made in view of such circumstances, and an object of the present invention is to provide an external preparation for skin that suppresses stickiness while sufficiently exhibiting the moisturizing effect of mucopolysaccharide.
【0006】[0006]
【課題を解決するための手段】本発明者は、上記課題を
解決するため鋭意研究を行なった結果、ムコ多糖と共
に、生体膜の主成分であるリン脂質(ホスファチジルコ
リン)の極性基と同一の構造を有する2−メタクリロイ
ルオキシエチルホスホリルコリンを構成単位とするポリ
マー物質を併用すると上記課題が解決されることを見い
出し、これに基づいて本発明を完成した。Means for Solving the Problems As a result of intensive studies to solve the above problems, the present inventor has found that, along with mucopolysaccharide, the same structure as the polar group of phospholipid (phosphatidylcholine), which is the main component of biological membranes. It was found that the above problem can be solved by using a polymer substance containing 2-methacryloyloxyethylphosphorylcholine as a constitutional unit in combination, and based on this, the present invention was completed.
【0007】すなわち、本発明は、ムコ多糖の少なくと
も一種以上と2−メタクリロイルオキシエチルホスホリ
ルコリンの重合体とを含有することを特徴とする皮膚外
用剤に関するものである。That is, the present invention relates to a skin external preparation containing at least one mucopolysaccharide and a polymer of 2-methacryloyloxyethylphosphorylcholine.
【0008】以下、本発明を詳細に説明する。まず、本
発明で適用されるムコ多糖は、例えばヒアルロン酸、コ
ンドロイチン−4−硫酸、コンドロイチン−6−硫酸、
デルマタン硫酸、ケラタン硫酸、ヘパリノイド、ヘパリ
ン等、またはこれらの塩などが挙げられ、これらの中か
ら少なくとも一種以上が選択して用いられる。Hereinafter, the present invention will be described in detail. First, mucopolysaccharides applied in the present invention include, for example, hyaluronic acid, chondroitin-4-sulfate, chondroitin-6-sulfate,
Examples thereof include dermatan sulfate, keratan sulfate, heparinoid, heparin and the like, and salts thereof, and at least one kind or more is selected and used from these.
【0009】その配合量としては、皮膚外用剤全体に対
して0.001〜5重量%、好ましくは0.01〜3重
量%である。0.001重量%より少ない量では保湿効
果に乏しく、また5重量%を越える量となると2−メタ
クリロイルオキシエチルホスホリルコリンの重合体を併
用してもべたつきを抑えることが困難となる。The compounding amount thereof is 0.001 to 5% by weight, preferably 0.01 to 3% by weight, based on the whole skin external preparation. When the amount is less than 0.001% by weight, the moisturizing effect is poor, and when the amount is more than 5% by weight, it becomes difficult to suppress stickiness even when the polymer of 2-methacryloyloxyethylphosphorylcholine is used in combination.
【0010】次に、本発明に適用される重合体は、下記
化1に示す一般式(I)で示される2−メタクリロイル
オキシエチルホスホリルコリン(以下MPCと略記)を
重合させて得られるものである。Next, the polymer applied to the present invention is obtained by polymerizing 2-methacryloyloxyethylphosphorylcholine (hereinafter abbreviated as MPC) represented by the general formula (I) shown below. .
【0011】[0011]
【化1】 Embedded image
【0012】かかるMPCについては、例えば2−ブロ
モエチルホスホリルジクロリドと2−ヒドロキシエチル
ホスホリルジクロリドと2−ヒドロキシエチルメタクリ
レートとを反応させて2−メタクリロイルオキシエチル
−2′−ブロモエチルリン酸を得、更にこれをトリメチ
ルアミンとメタノール溶液中で反応させて得ることがで
きる。(高分子論文集,Vol.35,P423〜427,
1978)Regarding such MPC, for example, 2-bromoethylphosphoryldichloride, 2-hydroxyethylphosphoryldichloride and 2-hydroxyethylmethacrylate are reacted to obtain 2-methacryloyloxyethyl-2'-bromoethylphosphoric acid, and further It can be obtained by reacting this with trimethylamine in a methanol solution. (Polymer Papers, Vol.35, P423-427,
(1978)
【0013】次に、重合体の製造方法については常法に
従えば良く、MPCを溶媒中で重合開始剤の存在下、反
応させて得られる。ここで使用される溶媒としては、M
PCが溶解するものであれば良く、具体的には水、メタ
ノール、エタノール、プロパノール、t−ブタノール、
ベンゼン、トルエン、ジメチルホルムアミド、テトラヒ
ドロフラン、クロロホルムまたはこれらの混合溶媒等が
例示される。また、重合開始剤としては、通常のラジカ
ル開始剤ならば何れを用いても良く、2,2′−アゾビ
スイソブチロニトリル(AIBN)、アゾビスマレノニ
トリル等の脂肪酸アゾ化合物や過酸化ベンゾイル、過酸
化ラウロイル、過硫酸カリウム等の有機過酸化物を挙げ
ることができる。Next, the method for producing the polymer may be carried out according to a conventional method, which is obtained by reacting MPC in a solvent in the presence of a polymerization initiator. The solvent used here is M
Any substance that can dissolve PC may be used. Specifically, water, methanol, ethanol, propanol, t-butanol,
Examples thereof include benzene, toluene, dimethylformamide, tetrahydrofuran, chloroform or a mixed solvent thereof. As the polymerization initiator, any ordinary radical initiator may be used, and fatty acid azo compounds such as 2,2′-azobisisobutyronitrile (AIBN) and azobismalenonitrile, and benzoyl peroxide. Examples thereof include organic peroxides such as lauroyl peroxide and potassium persulfate.
【0014】以下に、本発明に係る重合体の製造例を示
す。 製造例1.2−メタクリロイルオキシエチルホスホリル
コリンの重合体(以下、Poly(MPC)と略記) MPCを0.5モル/lとなるようにエタノールに溶解
し、重合開始剤としてAIBNをモノマーに対して1モ
ル%加える。溶液をガラス製反応器に入れアルゴンで充
分に置換した後、密封した。これを60℃下、4時間加
温して重合反応を行なった。反応混合物を氷冷した後、
1.8lのジエチルエーテル中に滴下してポリマーを沈
殿させた。これをロ別し、充分にジエチルエーテルで洗
浄した後、減圧乾燥して白色粉末状のPoly(MP
C)を得た。収率60%。The production examples of the polymer according to the present invention are shown below. Production Example 1. Polymer of 2-methacryloyloxyethylphosphorylcholine (hereinafter, abbreviated as Poly (MPC)) MPC was dissolved in ethanol at 0.5 mol / l, and AIBN was used as a polymerization initiator with respect to the monomer. Add 1 mol%. The solution was placed in a glass reactor, sufficiently replaced with argon, and then sealed. This was heated at 60 ° C. for 4 hours to carry out a polymerization reaction. After cooling the reaction mixture on ice,
The polymer was precipitated by dropping into 1.8 l of diethyl ether. This was separated by filtration, washed thoroughly with diethyl ether, and then dried under reduced pressure to give a white powdery Poly (MP
C) was obtained. Yield 60%.
【0015】上記の如くして得られる本発明に係るPo
ly(MPC)の分子量は、自身の保湿能、感触面等を
勘案した場合、通常はポリスチレン換算で5,000以
上であり、好ましくは10,000以上である。Po according to the present invention obtained as described above
The molecular weight of ly (MPC) is usually 5,000 or more, preferably 10,000 or more in terms of polystyrene, in consideration of its moisturizing ability, touch surface and the like.
【0016】ここで、Poly(MPC)の配合量は皮
膚外用剤全体に対して、0.001〜10重量%、好ま
しくは0.01〜3重量%の範囲である。Here, the amount of Poly (MPC) compounded is in the range of 0.001 to 10% by weight, preferably 0.01 to 3% by weight, based on the total skin external preparation.
【0017】また、本発明の皮膚外用剤は、通常の皮膚
外用剤例えばローション剤、クリーム剤、粉末剤などの
形態で、また化粧水、乳液、クリーム、口紅、ファンデ
ーション、ヘアートニック、ヘアークリーム、ヘアーロ
ーションなどの化粧料形態で用いることができる。この
中でもローション剤や化粧水の場合が最も好ましいもの
となる。尚、これらの皮膚外用剤は常法に従って製造す
ることができる。Further, the external preparation for skin of the present invention is in the form of an ordinary external preparation for skin such as lotion, cream, powder, and lotion, emulsion, cream, lipstick, foundation, hair heric, hair cream, It can be used in a cosmetic form such as a hair lotion. Of these, lotions and lotions are the most preferable. In addition, these external preparations for skin can be manufactured by a conventional method.
【0018】更に、本発明の皮膚外用剤には、必要に応
じて界面活性剤、粉体又は顔料、酸化防止剤、紫外線吸
収剤、ビタミン類、防腐剤、香料などを配合できる。Further, the external preparation for skin of the present invention may contain a surfactant, powder or pigment, antioxidant, ultraviolet absorber, vitamins, preservative, fragrance and the like, if necessary.
【0019】[0019]
【発明の実施の形態】及びDETAILED DESCRIPTION OF THE INVENTION AND
【実施例】以下に、本発明の皮膚外用剤の実施例を示
す。尚、実施例中の配合割合は重量部である。EXAMPLES Examples of the external preparation for skin of the present invention will be shown below. In addition, the compounding ratio in an Example is a weight part.
【0020】 実施例1 水中油型クリ−ム (A)POE(30)セチルエ−テル 2 グリセリンモノステアレ−ト 10 流動パラフィン 10 ワセリン 4 セタノール 5 2−ヒドロキシ−4−メトキシベンゾフェノン 3 γ−トコフェロ−ル 0.05 BHT 0.01 ブチルパラベン 0.1 (B)プロピレングリコ−ル 10 ムチン 0.1 コラーゲン加水分解物 0.3 水溶性胸腺エキス 0.2 ヒアルロン酸ナトリウム 0.01 Poly(MPC) 0.5 精製水 54.53 (C)香料 0.2Example 1 Oil-in-Water Cream (A) POE (30) Cetyl Ether 2 Glycerin Monostearate 10 Liquid Paraffin 10 Vaseline 4 Cetanol 5 2-Hydroxy-4-methoxybenzophenone 3 γ-tocophero- Le 0.05 BHT 0.01 butyl paraben 0.1 (B) propylene glycol 10 mucin 0.1 collagen hydrolysate 0.3 water-soluble thymus extract 0.2 sodium hyaluronate 0.01 Poly (MPC) 0 .5 Purified water 54.53 (C) Perfume 0.2
【0021】(製法)(A)の各成分に合わせ、80℃
に加熱する。(B)の各成分を合わせ、80℃に加熱す
る。(A)の処方分を(B)の処方分を加えて攪はん乳
化し、その後(C)を加えて冷却する。(Manufacturing method) 80 ° C. according to each component of (A)
Heat to. The components of (B) are combined and heated to 80 ° C. The prescription of (A) is added to the prescription of (B) and stirred to emulsify. Thereafter, (C) is added and cooled.
【0022】 実施例2 水中油型クリ−ム (A)POE(30)セチルエ−テル 2 グリセリンモノステアレ−ト 10 流動パラフィン 10 ワセリン 4 セタノール 5 スフィンゴ糖脂質 0.1 δートコフェロール 0.05 2−エチルヘキシルパラジメチルアミノベンゾエート 3 4ーメトキシー4’ーt−ブチルージベンゾイルメタン 1 グリチルレチン酸 0.1 酸化チタン 1 BHT 0.01 ブチルパラベン 0.1 (B)桑白皮エキス 0.1 当帰エキス 0.1 パンテテイン−s−スルフォン酸カルシウム 1 ケラタン硫酸 1 Poly(MPC) 1 プロピレングリコール 10 精製水 50.34 (C)香料 0.1Example 2 Oil-in-Water Cream (A) POE (30) Cetyl Ether 2 Glycerin Monostearate 10 Liquid Paraffin 10 Vaseline 4 Cetanol 5 Sphingoglycolipid 0.1 δ Tocopherol 0.05 2 -Ethylhexyl paradimethylaminobenzoate 34-methoxy-4'-t-butyl-dibenzoylmethane 1 Glycyrrhetinic acid 0.1 Titanium oxide 1 BHT 0.01 Butylparaben 0.1 (B) Mulberry peel extract 0.1 Toki extract 0 .1 Pantetheine-s-calcium sulfonate 1 Keratan sulfate 1 Poly (MPC) 1 Propylene glycol 10 Purified water 50.34 (C) Perfume 0.1
【0023】(製法)(A)の各成分に合わせ、80℃
に加熱する。(B)の各成分を合わせ、80℃に加熱す
る。(A)の処方分を(B)の処方分を加えて攪はん乳
化し、その後(C)を加えて冷却する。(Manufacturing method) 80 ° C. according to each component of (A)
Heat to. The components of (B) are combined and heated to 80 ° C. The prescription of (A) is added to the prescription of (B) and stirred to emulsify. Thereafter, (C) is added and cooled.
【0024】 実施例3 乳液 (A)合成ゲイロウ 2.5 セタノール 1 スクワラン 4 ステアリン酸 1 モノステアリン酸ポリエチレングリコール(25EO) 2.2 モノステアリン酸グリセリン 0.5 ステロールグルコシド 0.1 2−エチルヘキシルパラジメチルアミノベンゾエート 2 イソフェルラ酸ナトリウム 1 アラントイン 0.1 酸化亜鉛 1 ブチルパラベン 0.1 γ−トコフェロール 0.05 ローズマリーエキス 0.01 エデト酸2ナトリウム 0.2 (B)1、3−ブチレングリコール 3 プロピレングリコール 7 マロニエエキス 0.1 キサンタンガム 0.1 苛性カリ 0.2 アスコルビン酸リン酸マグネシウム塩 1 アルブチン 2 キチン加水分解物 0.2 コンドロイチン−6−硫酸 3 Poly(MPC) 3 精製水 64.54 (C)香料 0.1Example 3 Emulsion (A) Synthetic Geiro 2.5 Cetanol 1 Squalane 4 Stearic acid 1 Polyethylene glycol monostearate (25EO) 2.2 Glycerin monostearate 0.5 Sterol glucoside 0.1 2-Ethylhexyl paradimethyl Aminobenzoate 2 Sodium isoferurate 1 Allantoin 0.1 Zinc oxide 1 Butylparaben 0.1 γ-Tocopherol 0.05 Rosemary extract 0.01 Edetate disodium 0.2 (B) 1,3-Butylene glycol 3 Propylene glycol 7 Horse chestnut extract 0.1 Xanthan gum 0.1 Caustic potassium 0.2 Magnesium ascorbyl phosphate 1 Arbutin 2 Chitin hydrolyzate 0.2 Chondroitin-6-sulfate 3 Poly (MPC) 3 Purification Water 64.54 (C) Perfume 0.1
【0025】(製法)(A)及び(B)を70℃で各々
攪反しながら溶解する。(B)に(A)を加え予備乳化
を行いホモミキサーで均一に乳化し、乳化後、(C)を
加えてかき混ぜながら30℃まで冷却する。(Production method) (A) and (B) are dissolved at 70 ° C. with stirring. (A) is added to (B), preliminarily emulsified, and uniformly emulsified by a homomixer. After emulsification, (C) is added, and the mixture is cooled to 30 ° C. while stirring.
【0026】 実施例4 乳液 (A)合成ゲイロウ 1.5 セタノール 0.5 流動パラフィン 5 モノステアリン酸ポリエチレングリコール(25EO) 2 モノステアリン酸グリセリン 0.4 p−メトキシケイ皮酸−2−エチルヘキシルエステル 4 酸化チタン 0.5 ブチルパラベン 0.1 γ−トコフェロール 0.05 BHT 0.01 (B)1、3−ブチレングリコール 3 プロピレングリコール 5 カルボキシビニルポリマー 0.3 ヒアルロン酸ナトリウム 0.1 ローヤルゼリー 0.3 イチョウエキス 0.1 オウゴンエキス 0.2 Poly(MPC) 1 精製水 75.8 (C)香料 0.14Example 4 Emulsion (A) Synthetic Geyrow 1.5 Cetanol 0.5 Liquid paraffin 5 Polyethylene glycol monostearate (25EO) 2 Glycerin monostearate 0.4 p-Methoxycinnamic acid-2-ethylhexyl ester 4 Titanium oxide 0.5 Butylparaben 0.1 γ-Tocopherol 0.05 BHT 0.01 (B) 1,3-butylene glycol 3 Propylene glycol 5 Carboxyvinyl polymer 0.3 Sodium hyaluronate 0.1 Royal jelly 0.3 Ginkgo Extract 0.1 Ogon extract 0.2 Poly (MPC) 1 Purified water 75.8 (C) Perfume 0.14
【0027】(製法)(A)及び(B)を70℃で各々
攪反しながら溶解する。(B)に(A)を加え予備乳化
を行いホモミキサーで均一に乳化し、乳化後、(C)を
加えてかき混ぜながら30℃まで冷却する。(Production method) (A) and (B) are dissolved at 70 ° C. with stirring. (A) is added to (B), preliminarily emulsified, and uniformly emulsified by a homomixer. After emulsification, (C) is added, and the mixture is cooled to 30 ° C. while stirring.
【0028】 実施例5 化粧水 (A)POE(20)ソルビタンモノラウリン酸エステル 1.5 POE(20)ラウリルエステル 0.5 エタノール 10 p−メトキシケイ皮酸−2−エチルヘキシルエステル 3 イソフェルラ酸ナトリウム 0.2 グリチルレチン酸ステアリル 0.5 γ−トコフェロール 0.02 香料 0.1 (B)グリセリン 5 プロピレングリコール 4 クエン酸 0.15 クエン酸ナトリウム 0.1 アスコルビン酸リン酸マグネシウム塩 3 胎盤抽出物 0.1 牛血液除蛋白エキス 0.1 ヘパリノイド 0.1 ヘパリン 0.1 Poly(MPC) 0.1 色素 0.1 精製水 71.33Example 5 Lotion (A) POE (20) sorbitan monolauric acid ester 1.5 POE (20) lauryl ester 0.5 ethanol 10 p-methoxycinnamic acid-2-ethylhexyl ester 3 sodium isoferric acid 0. 2 Stearyl glycyrrhetinate 0.5 γ-tocopherol 0.02 Perfume 0.1 (B) Glycerin 5 Propylene glycol 4 Citric acid 0.15 Sodium citrate 0.1 Ascorbic acid magnesium phosphate 3 Placenta extract 0.1 Beef Blood deproteinization 0.1 Heparinoid 0.1 Heparin 0.1 Poly (MPC) 0.1 Pigment 0.1 Purified water 71.33
【0029】(製法)(A)の各成分を合わせ、室温下
に溶解する。一方、(B)の各成分も室温下に溶解し、
これを(A)処方分に加えて可溶化する。(Manufacturing method) The components of (A) are combined and dissolved at room temperature. On the other hand, each component of (B) also dissolves at room temperature,
This is added to the (A) formulation and solubilized.
【0030】 実施例6 化粧水 (A)POE(20)ソルビタンモノランリン酸エステル 1.5 POE(20)ラウリルエステル 0.5 エタノール 8 2−エチルヘキシルパラジメチルアミノベンゾエート 2 4ーメトキシー4’ーt−ブチルージベンゾイルメタン 3 γ−オリザノール 0.3 γ−トコフェロール 0.02 (B)グリセリン 5 1,3−ブチレングリコール 4 クエン酸 0.15 クエン酸ナトリウム 0.1 エチニルエストラジオール 0.001 ゲンノショウコエキス 0.1 セリン 0.1 ヒアルロン酸ナトリウム 0.5 Poly(MPC) 0.5 色素 0.1 精製水 74.129Example 6 Lotion (A) POE (20) sorbitan monolan phosphate 1.5 POE (20) lauryl ester 0.5 ethanol 8 2-ethylhexyl paradimethylaminobenzoate 2 4-methoxy-4'-t-butyl Luge benzoyl methane 3 γ-oryzanol 0.3 γ-tocopherol 0.02 (B) glycerin 5 1,3-butylene glycol 4 citric acid 0.15 sodium citrate 0.1 ethinyl estradiol 0.001 gem ginger extract 0.1 serine 0.1 Sodium hyaluronate 0.5 Poly (MPC) 0.5 Dye 0.1 Purified water 74.129
【0031】(製法)(A)の各成分を合わせ、室温下
に溶解する。一方、(B)の各成分も室温下に溶解し、
これを(A)処方分に加えて可溶化する。(Production method) The respective components of (A) are combined and dissolved at room temperature. On the other hand, each component of (B) also dissolves at room temperature,
This is added to the (A) formulation and solubilized.
【0032】 実施例7 パック料 (A)ポリビニルアルコ−ル 15 精製水 40 ビサボロ−ル 0.5 ビタミンA酸 0.2 γ−トコフェロール 0.02 イソフェルラ酸ナトリウム 0.1 酸化チタン 10 (B)エタノ−ル 4 1,3−ブチレングリコ−ル 4 ポリオキシエチレン(8)ポリオキシ プロピレングリコ−ル(55) 3 シャクヤクエキス 0.3 アロエエキス 0.4 コンドロイチン硫酸カリウム 0.01 トウニンエキス 0.3 Poly(MPC) 0.05 精製水 21.12Example 7 Packing Material (A) Polyvinyl Alcohol 15 Purified Water 40 Bisaborole 0.5 Vitamin A Acid 0.2 γ-Tocopherol 0.02 Sodium Isoferulate 0.1 Titanium Oxide 10 (B) Ethano -Lol 4,1,3-butylene glycol 4 Polyoxyethylene (8) Polyoxy propylene glycol (55) 3 Peony extract 0.3 Aloe extract 0.4 Chondroitin sulfate 0.01 Tonin extract 0.3 Poly (MPC ) 0.05 purified water 21.12
【0033】(製法)(A)を室温にて分散溶解する。
これに(B)を加えて均一に溶解する。(Production method) (A) is dispersed and dissolved at room temperature.
(B) is added thereto and uniformly dissolved.
【0034】上記実施例1〜7で得られた本発明の皮膚
外用剤について、女子官能パネラー5名を用いて、実使
用官能試験を行ったところ、何れも優れた保湿効果を示
し、一方べたつきについては充分に抑制されていること
が立証された。The external preparations for skin of the present invention obtained in Examples 1 to 7 above were subjected to a sensory test in actual use by using 5 female sensory panelists. All of them showed an excellent moisturizing effect, while they were greasy. Was proved to be sufficiently suppressed.
【0035】[0035]
【発明の効果】本発明によれば、ムコ多糖に基づく保湿
効果に優れると共にべたつきを感じさせない皮膚外用剤
を提供することができる。INDUSTRIAL APPLICABILITY According to the present invention, it is possible to provide a skin external preparation that is excellent in moisturizing effect based on mucopolysaccharide and does not cause stickiness.
Claims (2)
タクリロイルオキシエチルホスホリルコリンの重合体と
を含有することを特徴とする皮膚外用剤。1. An external preparation for skin, comprising at least one mucopolysaccharide and a polymer of 2-methacryloyloxyethylphosphorylcholine.
請求項1に記載の皮膚外用剤。2. The external preparation for skin according to claim 1, wherein the polymer has a molecular weight of 5,000 or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22113795A JPH0952848A (en) | 1995-08-07 | 1995-08-07 | Skin preparation for external use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP22113795A JPH0952848A (en) | 1995-08-07 | 1995-08-07 | Skin preparation for external use |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0952848A true JPH0952848A (en) | 1997-02-25 |
Family
ID=16762046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP22113795A Pending JPH0952848A (en) | 1995-08-07 | 1995-08-07 | Skin preparation for external use |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0952848A (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09122224A (en) * | 1995-11-02 | 1997-05-13 | Toyobo Co Ltd | Anticoagulant material |
JP2000086536A (en) * | 1998-09-18 | 2000-03-28 | Nof Corp | Preservative composition |
JP2001002552A (en) * | 1999-06-23 | 2001-01-09 | Pola Chem Ind Inc | Skin protective cosmetic |
WO2003026606A1 (en) * | 2001-09-25 | 2003-04-03 | Sekisui Chemical Co., Ltd. | Compositions for improving skin barrier function |
JP2003160462A (en) * | 2001-11-21 | 2003-06-03 | Pola Chem Ind Inc | Functional skin care preparation having barrier function |
JP2005179326A (en) * | 2003-12-15 | 2005-07-07 | Iona International Corp | Cosmetic |
JP2006008520A (en) * | 2004-06-22 | 2006-01-12 | Pola Chem Ind Inc | Moisture-retaining cosmetic |
JP2009215298A (en) * | 2008-03-11 | 2009-09-24 | L'oreal Sa | Cosmetic composition containing ascorbic acid or salicylic acid compound |
WO2012008457A1 (en) * | 2010-07-12 | 2012-01-19 | ロート製薬株式会社 | Composition for external application |
JP2012036176A (en) * | 2010-07-16 | 2012-02-23 | Rohto Pharmaceutical Co Ltd | Composition for external use |
JP2012036174A (en) * | 2010-07-12 | 2012-02-23 | Rohto Pharmaceutical Co Ltd | Composition for external application |
JP2013053088A (en) * | 2011-09-02 | 2013-03-21 | Pola Chemical Industries Inc | Powder-containing external skin care preparation |
JP2017178876A (en) * | 2016-03-31 | 2017-10-05 | 花王株式会社 | Skin care methods |
JP2020117550A (en) * | 2009-01-09 | 2020-08-06 | ロート製薬株式会社 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
JP2021175753A (en) * | 2016-12-28 | 2021-11-04 | 小林製薬株式会社 | External composition |
-
1995
- 1995-08-07 JP JP22113795A patent/JPH0952848A/en active Pending
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09122224A (en) * | 1995-11-02 | 1997-05-13 | Toyobo Co Ltd | Anticoagulant material |
JP4536175B2 (en) * | 1998-09-18 | 2010-09-01 | 日油株式会社 | Preservative composition |
JP2000086536A (en) * | 1998-09-18 | 2000-03-28 | Nof Corp | Preservative composition |
JP2001002552A (en) * | 1999-06-23 | 2001-01-09 | Pola Chem Ind Inc | Skin protective cosmetic |
WO2003026606A1 (en) * | 2001-09-25 | 2003-04-03 | Sekisui Chemical Co., Ltd. | Compositions for improving skin barrier function |
JP2003160462A (en) * | 2001-11-21 | 2003-06-03 | Pola Chem Ind Inc | Functional skin care preparation having barrier function |
JP2005179326A (en) * | 2003-12-15 | 2005-07-07 | Iona International Corp | Cosmetic |
JP2006008520A (en) * | 2004-06-22 | 2006-01-12 | Pola Chem Ind Inc | Moisture-retaining cosmetic |
JP2009215298A (en) * | 2008-03-11 | 2009-09-24 | L'oreal Sa | Cosmetic composition containing ascorbic acid or salicylic acid compound |
JP2020117550A (en) * | 2009-01-09 | 2020-08-06 | ロート製薬株式会社 | Method for inhibiting discoloration of composition for external use containing diphenhydramine or salt thereof and ascorbic acid or salt thereof |
WO2012008457A1 (en) * | 2010-07-12 | 2012-01-19 | ロート製薬株式会社 | Composition for external application |
JP2012036174A (en) * | 2010-07-12 | 2012-02-23 | Rohto Pharmaceutical Co Ltd | Composition for external application |
JP2012036176A (en) * | 2010-07-16 | 2012-02-23 | Rohto Pharmaceutical Co Ltd | Composition for external use |
JP2015232032A (en) * | 2010-07-16 | 2015-12-24 | ロート製薬株式会社 | External composition |
JP2013053088A (en) * | 2011-09-02 | 2013-03-21 | Pola Chemical Industries Inc | Powder-containing external skin care preparation |
JP2017178876A (en) * | 2016-03-31 | 2017-10-05 | 花王株式会社 | Skin care methods |
JP2021175753A (en) * | 2016-12-28 | 2021-11-04 | 小林製薬株式会社 | External composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2689774B1 (en) | Reversely thermo-reversible hydrogel compositions | |
JPH0952848A (en) | Skin preparation for external use | |
JP4236064B2 (en) | Cosmetic composition containing low crystalline cellulose fine particles | |
JP2002003373A (en) | Skin care preparation | |
JP2001081008A (en) | Skin preparation for external use keeping and improving the skin from chapping | |
JPH07233045A (en) | Skin external preparation | |
JPH09315937A (en) | Gelled composition, emulsion composition and preparation for external use for skin | |
JPS63166815A (en) | Skin external preparation | |
JPH01275511A (en) | External drug for skin | |
JPS63301826A (en) | Drug for external use | |
JPH09235301A (en) | New polysaccharide derivative, its production and cosmetic containing the same | |
JP2001278783A (en) | Collagen production promoter | |
JP2003095844A (en) | Cosmetic | |
JP2604782B2 (en) | Cosmetics | |
JPH10279419A (en) | Preparation for external use for skin | |
WO1994001075A1 (en) | Composition for dermatologic preparation | |
JPS62169711A (en) | Skin cosmetic | |
JP2004075635A (en) | Moisturizing agent and external preparation for skin | |
JPH09124437A (en) | Emulsified composition and dermal preparation for external use | |
JPH06122621A (en) | External agent for skin | |
JP3234041B2 (en) | External preparation for skin | |
WO1992006667A1 (en) | External preparation for skin | |
JP2002284635A (en) | External skin preparation | |
JPH11116604A (en) | External preparation for skin | |
JPH10120521A (en) | Translucent cosmetic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Effective date: 20040210 Free format text: JAPANESE INTERMEDIATE CODE: A02 |